Doctor's dilemma: Incorporating tumor markers into clinical decision-making

Seminars in Oncology

Volumn 29, Issue 3, 2002, Pages 286-293

  Canil, Christina M ^a   Tannock, Ian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; LACTATE DEHYDROGENASE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER THERAPY; CASE REPORT; CHORIOCARCINOMA; COLON CANCER; EMBRYONAL CARCINOMA; FEMALE; GERM CELL TUMOR; HUMAN; MALE; MEDICAL DECISION MAKING; ORCHIECTOMY; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RELAPSE; TESTIS TUMOR;

EID: 0036272425     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.32904     Document Type: Article

References (40)

1. Guide to studies of diagnostic tests, prognostic factors and treatments
2. Breast cancer screening with mammography: Overview of Swedish randomized trials
3. Efficacy of screening mammography among women aged 40-49 years and 50 to 69 years: Comparison of relative and absolute benefit
4. Periodic screening for breast cancer: The HIP randomized controlled trial
5. Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
6. Prostate-specific antigen best practice policy - Part I: Early detection and diagnosis of prostate cancer
7. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute
8. Statistical considerations and modeling of clinical utility of tumor markers
9. Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience
10. Tumor marker relapse in patients with non-seminomatous germ cell tumors
11. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers
12. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer
13. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
14. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints
15. A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer
16. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer
17. Carcinoembryonic antigen
18. Cancer markers
19. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology
20. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial
21. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases
22. A meta-analysis of two randomized trials of early chemotherapy in asymptomatic metastatic colorectal cancer
23. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel
24. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
25. Followup of patients with colorectal cancer
26. Follow-up of colorectal cancer: A meta-analysis
27. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer
28. Postsurgical surveillance of colon cancer: Preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy
29. Tumor markers at the time of recurrence in patients with germ cell tumors
30. Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either vinblastine or etoposide
31. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors
32. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the CALGB 9182 study
33. Analysis of survival by tumor response
34. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
35. PSAdynia and other PSA-related syndromes: A new epidemic - A case history and toxonomy
36. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers
37. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer